Premium
Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody
Author(s) -
Katsumi S.,
Kobayashi N.,
Yamamoto Y.,
Miyagawa S.,
Shirai T.
Publication year - 2000
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2000.03492.x
Subject(s) - scleroderma (fungus) , medicine , antibody , systemic disease , connective tissue disease , immunology , clinical significance , autoimmune disease , systemic scleroderma , anti nuclear antibody , lupus erythematosus , autoantibody , disease , dermatology , pathology , immunopathology , inoculation
We describe a patient with systemic lupus erythematosus (SLE) associated with topoisomerase I (topo I, Scl‐70) antibody, a specific marker for systemic sclerosis (SSc). SSc patients who produce this antibody have severe cutaneous and visceral involvement, and eventually have a poor prognosis. It is rare to find this antibody in patients with other collagen diseases. Only four SLE patients have been reported in the English language literature who were topo I antibody‐positive but had no clinical evidence of scleroderma. The serum of our patient with SLE had precipitating topo I antibody from the onset of his disease. Twelve years after the onset of SLE, he developed proximal scleroderma and pulmonary fibrosis. This case reconfirms the prognostic significance of topo I antibody as a predictive marker, and indicates that SLE patients with topo I antibody require careful follow‐up for future development of scleroderma.